Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Dose Emicizumab vs FVIII Prophylaxis in Hemophilia A
NCT06155955Phase 3Recruiting
- Sponsor
- Chulalongkorn University
- Start
- Jun 2023
- Primary completion
- Mar 2024
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label trial of emicizumab in hemophilia A (2 arms), sponsored by Chulalongkorn University. Primary endpoints: Spontaneous and Traumatic Bleeding Rate at 6 months, Treated Spontaneous and Joint Bleeds at 6 months and 1 more. Started Jun 2023; status: recruiting.
02
Drugs
emicizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT06155955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06155955.